VivoSeq
Other

Hyperkalemia

12

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Hyperkalemia is an emerging landscape with 12 programs across 9 companies. The most active players are Waterstone Pharmaceutical (Wuhan) Co., LTD., Vifor Pharma, AstraZeneca. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

W

Waterstone Pharmaceutical (Wuhan) Co., LTD.

1 program

Phase 2V

Vifor Pharma

1 program

Phase 3AstraZeneca logo

AstraZeneca

3 programs

Phase 3Otsuka logo

Otsuka

1 program

ApprovedGSK logo

GSK

1 program

ApprovedV

Vifor Fresenius Medical Care Renal Pharma

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

26

clinical trials

Completed18 · 69%
Terminated4 · 15%
Recruiting2 · 8%
Unknown status2 · 8%

Clinical Trials

Trial Activity

26 trials

A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
Recruiting·WWaterstone Pharmaceutical (Wuhan) Co., LTD.·Phase 3·NCT07251309·420 enrolled
Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia
Recruiting·NNantes University Hospital·Phase 4·NCT04012138·525 enrolled
Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
Completed·ZZeria Pharmaceutical·Phase 2·NCT03799926·184 enrolled
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
Completed·—·Phase 2·NCT03326583·27 enrolled
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Completed·ZZS Pharma, Inc.·Phase 3·NCT02107092·123 enrolled
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Completed·GGuangdong Provincial People's Hospital·Phase 3·NCT05382988·62 enrolled
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT02875834·267 enrolled
Patiromer With or Without Food for the Treatment of Hyperkalemia
Completed·RRelypsa, Inc.·Phase 4·NCT02694744·114 enrolled
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT03172702·150 enrolled
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Completed·—·Phase 4·NCT03781089·36 enrolled
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Completed·AArdelyx·Phase 2·NCT04780841·109 enrolled
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT03528681·270 enrolled
SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients
Completed·—·N/A·NCT06029179·120 enrolled
5 Versus 10 Units of Insulin in Hyperkalemia Management
Completed·OOman Medical Speciality Board·Phase 4·NCT06036823·384 enrolled
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
Completed·NNephroNet, Inc.·Phase 4·NCT05535920·88 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)